The Lundbeck Foundation to focus exclusively on Danish biotech

The majority stakeholder in pharmaceutical firm Lundbeck, the Lundbeck Foundation, is merging its two funds with one aim in mind: investing in Danish biotech companies.

Lene Skole, CEO at the Lundbeck Foundation | Photo: Gregers Tycho/ERH

Going forward, the Lundbeck Foundation, which is the majority stakeholder in pharmaceutical firm Lundbeck, will bet exclusively on Danish biotech companies, CEO at the Lundbeck Foundation Lene Skole tells Danish media Finans.

Specifically, the foundation will be merging its two funds, Ventures and Emerge, into one unit, dubbed Lundbeckfonden Biocapital.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs